HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced that Clinical Cancer Research published “Circulating Tumor Cells versus Imaging – Predicting Overall Survival in Metastatic Breast Cancer” in the November 1st issue. Principal author, G. Thomas Budd, MD of the Cleveland Clinic Foundation concluded, “Assessment of CTCs is an earlier, more reproducible indication of disease status than current imaging methods. CTCs may be a superior surrogate end point, as they are highly reproducible and correlate better with overall survival than do changes determined by traditional radiology.”
